Highlights Valneva

Equities

Market Closed - Euronext Paris Other stock markets 09:05:02 09/05/2024 pm IST			5-day change	1st Jan Change
3.256 ^EUR	+0.06%		-3.67%	-31.02%

07/05	Valneva SE Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
07/05	Transcript : Valneva SE, Q1 2024 Earnings Call, May 07, 2024

Valneva SE Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Valneva: quarterly results boosted by PRV sale	07/05	CF
Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024	07/05	CI
Valneva: Deep Track Biotechnology Master holds less than 5% of the capital	11/04	CF
Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate	26/03	MT
Valneva: Phase 1 trial initiated in the Zika virus	26/03	CF
Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate	26/03	CI
ADRs End Higher; XTL Biopharmaceuticals Climbs 129%	21/03	DJ
Valneva SE Raises Revenue Guidance for 2024	20/03	CI
Valneva SE Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
Valneva: share price down, forecasts below expectations	20/03	CF
French biotech company Valneva raises product sales guidance	20/03	RE
U.S. CDC Advisory Committee Recommends Use of Valneva?s Single-Dose Chikungunya Vaccine IXCHIQ	01/03	CI
Valneva: Ixchiq vaccine recommended by ACIP	29/02	CF
Valneva Se Announces Earnings Guidance for 2024	15/02	CI
Valneva: 26% increase in product sales in 2023	15/02	CF
VALNEVA : Oddo BHF confirms its recommendation on the stock	05/02	CF
Valneva Sells Tropical Disease Priority Review Voucher for $103 Million	05/02	MT
Valneva Sells Chikungunya Virus Vaccine’s Priority Review Voucher for $103 Million	05/02	MT
Valneva: sale of priority review warrant for Ixchiq	05/02	CF

No results for this search